ALK and non-small cell lung carcinoma: Agüloğlu (39) and Chang (40) predicted anaplastic lymphoma kinase (ALK) rearrangement and EGFR mutation status in NSCLC via radiomics models based on 18F-FDG PET/CT images, assisting in targeted therapy decisions.